Assignee
AGENEBIO INC
US·13 granted patents·10 pending applications·37 citations·filing 2014–2024
Top patents by PatentIndex Score
23 records- 0191US12291535B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2022·Granted May 6, 2025·2 cites·37 claims
- 0291US10815242B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2016·Granted Oct 27, 2020·7 cites·10 claims
- 0391US9801879B2Pyridazine derivatives, compositions and methods for treating cognitive impairmentAGENEBIO INC·Filed 2015·Granted Oct 31, 2017·10 cites·13 claims
- 0490US11312721B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2020·Granted Apr 26, 2022·2 cites·10 claims
- 0586US11142529B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2019·Granted Oct 12, 2021·6 cites·30 claims
- 0683US10925834B2Extended release pharmaceutical compositions of levetiracetamAGENEBIO INC·Filed 2016·Granted Feb 23, 2021·2 cites·14 claims
- 0782US10329301B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2014·Granted Jun 25, 2019·6 cites·40 claims
- 0878US11505555B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2017·Granted Nov 22, 2022·2 cites·22 claims
- 0973US2023172862A1Extended release pharmaceutical compositions of levetiracetamAGENEBIO INC·Filed 2022·Application pending·0 cites
- 1071US12024525B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2022·Granted Jul 2, 2024·0 cites·22 claims
- 1167US12528819B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2022·Granted Jan 20, 2026·0 cites·11 claims
- 1266US2021346299A1Extended release pharmaceutical compositions of levetiracetamAGENEBIO INC·Filed 2020·Application pending·0 cites
- 1363US2023270753A1Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairmentAGENEBIO INC·Filed 2021·Application pending·0 cites
- 1463US2022062296A1Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairmentAGENEBIO INC·Filed 2021·Application pending·0 cites
- 1562US2024132513A1Benzazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2023·Application pending·0 cites
- 1660US11414425B2Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2019·Granted Aug 16, 2022·0 cites·51 claims
- 1759US2025228820A1Methods for preventing or slowing the progression of cognitive decline or impairment in subjects displaying normal cognitive performanceAGENEBIO INC·Filed 2023·Application pending·0 cites
- 1857US2024238246A1Methods for preventing or slowing the progression of cognitive decline or impairment in subjectsAGENEBIO INC·Filed 2024·Application pending·0 cites
- 1955US2023279021A1Polymorphs of a gabaa alpha5 agonist and methods of using in the treatment of cognitive impairmentAGENEBIO INC·Filed 2021·Application pending·0 cites
- 2054US10159648B2Extended release pharmaceutical compositions of levetiracetamAGENEBIO INC·Filed 2016·Granted Dec 25, 2018·0 cites·25 claims
- 2151US2023098667A1Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2020·Application pending·0 cites
- 2248US11160785B2Methods and compositions for improving cognitive functionAGENEBIO INC·Filed 2014·Granted Nov 2, 2021·0 cites·1 claims
- 2347US2018170941A1Benzodiazepine derivatives, compositions, and methods for treating cognitive impairmentAGENEBIO INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →